# Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)

> **NCT05647278** · PHASE4 · COMPLETED · sponsor: **Zhang Xiaofeng,MD** · enrollment: 370 (actual)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Tegoprazan 50 mg, tablets, orally, qd
- **DRUG:** Esomeprazole 20mg BID
- **DRUG:** Tegoprazan 50 mg, tablets, orally, bid
- **DRUG:** amoxicillin +clarithromycin+colloidal bismuth pectin BID
- **DRUG:** amoxicillin 1000mg tid

## Key facts

- **NCT ID:** NCT05647278
- **Lead sponsor:** Zhang Xiaofeng,MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-01
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-10-31
- **Target enrollment:** 370 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05647278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05647278, "Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT05647278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*